Business Context and Reporting Period
Advanced Biomed Inc. (ADVB), an emerging growth company incorporated in Nevada, filed this Form 8-K on December 23, 2025. The report details a material definitive agreement and the subsequent completion of an asset disposition involving the company's wholly owned Hong Kong subsidiary.
Key Financial Metrics
This filing does not provide standard financial statements, revenue, profit, cash flow, or debt metrics. The primary financial data point disclosed is the transaction value for the asset sale:
- Transaction Price: US$23,000 for 100% of the issued and outstanding shares of Advanced Biomed (HK) Limited.
- Valuation Basis: Based on a valuation report commissioned by the Company.
Material Changes
The Company completed the sale of its Hong Kong subsidiary, Advanced Biomed (HK) Limited, to an unrelated third party, Wei Ha Hui, on December 23, 2025. This transaction resulted in the transfer of all intellectual property owned by the Hong Kong subsidiary, including assets held by its wholly owned subsidiary, Shanghai Sglcell Biotech Co., Ltd., to the Buyer. The transaction was unanimously approved by the Board of Directors.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the Company's assessment of operational risks. Management notes that actual results may differ materially from expressed expectations due to various risks and uncertainties described in other SEC filings. The Company disclaims any obligation to update these statements except as required by law. A press release announcing the completion of the disposition was issued on December 30, 2025.
Investor Verification Checklist
- Verify the strategic rationale for selling the Hong Kong subsidiary and its associated IP for a nominal sum of US$23,000.
- Review the full text of the Share Purchase Agreement (Exhibit 2.1) for undisclosed terms, conditions, or future obligations.
- Confirm the impact of this disposition on the Company's remaining operational assets and future revenue streams.
- Assess whether the transfer of Shanghai Sglcell Biotech Co., Ltd. IP affects the Company's core business capabilities.